Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment but remains ineffective in solid tumors. Here, we compared CD19-CAR and HER2-CAR T cells with identical backbones in matched tumor models. Strikingly, CD19-CAR T cells eradicated all tested CD19 + solid tumors in vivo , whereas HER2-CAR T cells failed to control matched HER2 + solid tumors. Superior CD19-CAR efficacy was associated with greater avidity, stronger signaling, and rapid degranulation. To harness these favorable properties for solid tumor treatment, we developed and compared bispecific Adaptors redirecting CD19-CAR T cell activity against HER2 + cancers. Our lead nanobody-based Adaptor 4 incorporating an albumin-binding VHH improves upon earlier designs by enhancing manufacturability and tumor infiltration while retaining systemic persistence. It induced complete tumor regression and prolonged survival in two solid tumor models. Mechanistically, Adaptor 4 enhanced CAR T cell-tumor cell engagement, signaling and intratumoral infiltration, accompanied by spatially distinct CAR T cell states and local inflammatory remodeling. Long-term tumor-free mice rejected tumor rechallenge, demonstrating durable antitumor protection. Importantly, Adaptor 4 remained effective when combined with CD19-CAR T cells generated from patients with advanced solid cancers. Together, these findings establish an enhanced Adaptor strategy redirecting clinically validated CD19-CAR T cells for solid tumor treatment.
No takes yet. Share an insight, caveat, or question.
Slaney et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: